MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome

Insulin Resistance Clinical Trial

Official title:

MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03142633
• Other study ID #: SJ-525
• Status: Completed
• Start date: September 9, 2016
• Est. completion date: May 23, 2017

Study information

• Verified date: March 2017
• Source: Holbaek Sygehus
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to explore the microRNA profile in serum of women with Polycystic Ovary Syndrome and investigate the correlation between the microRNA profile and markers of metabolic syndrome.

Description:

The study consist of 2 parts:

1. A cross-sectional study of a cohort of women with PCOS with analysis of materials from the established biobank. (the PICOLO cohort) Data and blood samples from 266 women with PCOS was collected from January 2010 - February 2013 as a part of the PICOLO collaboration: "PCOS, infertility, Cardiovascular and Obstetric risk markers and Long-term Outcome" at Holbaek Fertility Clinic and at Herlev Hospital.

Serum samples will be analysed with Reverse Transcript polymerase chain Reaction (RT-qPCR) for selected microRNAs.

2. A follow-up study of local participants from the PICOLO study. 90 of the participants were recruited at Holbaek Fertility Clinic.

Following tests will be performed at reexamination, in order to describe the clinical phenotype: Health interview, anthropometrics, acne score, Ferriman-Gallway score, blood pressure, Transvaginal ultrasound of uterus and ovaries, insulin Resistance (IR) assessed with Oral glucose Tolerance test (OGTT), Venous blood for hormone analysis and lipid status.

MicroRNA analysis with Taqman microRNA array will be performed on serum samples.

Detection and treatment of women with PCOS is a challenge due to the variability of the syndrome. If MiRNA could serve as marker of metabolic syndrome, it would be possible to detect and follow the women of greater risk at an earlier stage, and thereby preventing morbidity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: May 23, 2017
• Est. primary completion date: May 23, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Women between 18 and 40 years when included in the PICOLO study

• PCOS based on the Rotterdam 2003 consensus criteria

Exclusion Criteria:

• Contraceptive pills within 8 weeks from examination,

• endocrinological disease (i.e. type 1 diabetes thyroid dysfunction),

• Severe endometriosis (stage III and IV)

• Premature ovarian insufficiency,

• Breastfeeding women and

• Pregnancy.

Related Conditions & MeSH terms

• Insulin Resistance
• Metabolic Syndrome
• Polycystic Ovary Syndrome
• Syndrome

Locations

Country	Name	City	State
Denmark	Fertility Clinic,Department of Gynecology and Obstetrics	Holbaek

Sponsors (1)

Lead Sponsor	Collaborator
Holbaek Sygehus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MicroRNA profile	The change in relative expression of MicroRNA in women with PCOS will be assessed, using TaqMan microRNA arrays, comparing serum samples from baseline from an existing biobank with serum samples from a follow up visit.	MicroRNA analysis will be performed on serum from baseline visit (biobank material) and on serum obtained from a follow-up visit 5 years after baseline. The participants will be examined for 2 hours at follow up.
Secondary	Insulin Resistance and Type 2 Diabetes	Insulin Resistance will be assessed by Oral glucose Tolerance test (OGTT). Venous blood samples and measurement of glucose, serum insulin and C-peptid will be collected at -5, 0, 30 and 120 min after a 75 g glucose load. Impaired glucose tolerance will be assessed by calculation of BIGTTs1(insulin sensitivity index) and BIGTTAIR(Acute insulin response)	The participants will be examined for 2 hours, at a follow-up visit 5 years after the baseline visit.
Secondary	Blood Pressure	Evaluated > 140/90 mmHg	The participants will be examined for 2 hours, at a follow-up visit 5 years after the baseline visit.
Secondary	Abdominal obesity	Waist-Hip Ratio. Elevated > 0,85	The participants will be examined for 2 hours, at a follow-up visit 5 years after the baseline visit.
Secondary	Overweight	Defined: BMI > 25 kg/m2	The participants will be examined for 2 hours, at a follow-up visit 5 years after the baseline visit.
Secondary	Dyslipidemia	Defined as triglycerides > 1,7mmol/L, Total cholesterol > 5,0, LDL > 3,0 or HDL<1,0 mmol/L	The participants will be examined for 2 hours, at a follow-up visit 5 years after the baseline visit.
Secondary	PCOS status	Evaluated by Rotterdam (2003) criteria: 1. Polycystic Ovaries:Number of antral follicles >12, ovarian volume (length*depth*width/2) > 10 mL 2) Clinical (evaluated by Ferriman Gallway score) or biochemical signs of hyperandrogenism ( Free Testosterone > 0.034 nmol/Lor total testosterone >1.8 nmol/L) 3.Oligo or amenorrhea ´(>35 days between bleedings)	The participants will be examined for 2 hours, at a follow-up visit 5 years after the baseline visit.